KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Long-Term Debt Repayments (2020 - 2023)

Royalty Pharma's Long-Term Debt Repayments history spans 1 years, with the latest figure at $5.9 billion for Q3 2020.

  • For Q3 2020, Long-Term Debt Repayments changed N/A year-over-year to $5.9 billion; the TTM value through Dec 2022 reached $5.9 billion, changed N/A, while the annual FY2023 figure was $350.0 million, N/A changed from the prior year.
  • Long-Term Debt Repayments for Q3 2020 was $5.9 billion at Royalty Pharma, up from $5.2 billion in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $5.9 billion in Q3 2020 and bottomed at $5.2 billion in Q1 2020.